Table 1.
Baseline characteristics of ABA2 participants with chronic GVHD.
| Characteristic Total N =92 | Classic cGVHD N=57 (62% of patients with cGVHD) | ocGVHD N=35 (38% of patients with cGVHD) | P value |
|---|---|---|---|
| Age, median years (range) | 37.1 (7.9 – 76.2) | 54.5 (7.0 – 76.5) | 0.02 |
| Age group, no. (%) | 0.602 | ||
| Pediatric (age < 21) | 13 (22.8) | 6 (17.1) | |
| Adult (age ≥21) | 44 (77.2) | 29 (82.9) | |
| Mean platelet count (103/mcL) at cGVHD diagnosis (range) | 168 (82–301) | 152 (41–335) | 0.28 |
| Time to cGVHD diagnosis, median days from transplant (range) | 220 (43 – 364) | 191 (108 – 349) | 0.0516 |
| Treatment group, no. (%) | 0.59 | ||
| 8/8 Aba | 22 (38.6) | 14 (40) | |
| 8/8 Placebo | 20 (35.1) | 9 (25.7) | |
| 7/8 Aba | 15 (26.3) | 12 (34.3) | |
| Performance Score > 90%, no. (%) | 42 (73.7) | 27 (77.1) | 0.81 |
| Disease, no. (%) | 0.85 | ||
| AML | 23 (40.4) | 11 (31.4) | |
| ALL | 17 (29.8) | 10 (28.6) | |
| CML | 3 (5.3) | 2 (5.7) | |
| MDS | 12 (21.1) | 10 (28.6) | |
| HL | 0 (0) | 0 (0) | |
| Other | 2 (3.5) | 2 (5.7) | |
| Conditioning regimen, no. (%) | 0.11 | ||
| Busulfan/Fludarabine | 6 (10.5) | 0 (0) | |
| Busulfan/cyclophosphamide | 24 (42.1) | 14 (40) | |
| TBI/ cyclophosphamide | 18 (31.6) | 10 (28.6) | |
| Fludarabine/Melphalan | 9 (15.8) | 11 (31.4) | |
| Conditioning intensity, no. (%) | 0.12 | ||
| Myeloablative | 48 (84.2) | 24 (68.6) | |
| Reduced intensity | 9 (15.8) | 11 (31.4) | |
| Graft type, no. (%) | 0.82 | ||
| Peripheral blood | 37 (64.9) | 24 (68.6) | |
| Bone marrow | 20 (35.1) | 11 (31.4) | |